The plasma protein therapeutics market size was valued at USD 28.13 billion in 2023 and is expected to reach USD 44.01 billion by 2032, growing at a CAGR of 5.10% from 2023 to 2032.
Key Takeaways
- North America contributed more than 47% of revenue share in 2022.
- Asia-Pacific is estimated to expand the fastest CAGR between 2023 and 2032.
- By product type, the immunoglobulin segment has held the largest market share of 35% in 2022.
- By product type, the albumin segment is anticipated to grow at a remarkable CAGR of 6.5% between 2023 and 2032.
- By application, the hemophilia segment generated over 32% of revenue share in 2022.
- By application, the primary immunodeficiency disorder segment is expected to expand at the fastest CAGR over the projected period.
- By end user, the hospitals segment generated over 70% of revenue share in 2022.
- By end user, the other segment is expected to expand at the fastest CAGR over the projected period.
The Plasma Protein Therapeutics Market is a dynamic sector within the healthcare industry, primarily focused on the development and commercialization of therapeutic products derived from plasma. These products play a crucial role in treating a variety of rare and chronic diseases, such as hemophilia, immune deficiencies, and neurological disorders. The market has witnessed substantial growth in recent years, driven by advancements in technology, increasing awareness about plasma-derived therapies, and a rising global demand for improved healthcare solutions.
Get a Sample: https://www.precedenceresearch.com/sample/3630
Plasma Protein Therapeutics Market Scope
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 5.10% |
| Market Size in 2023 | USD 28.13 Billion |
| Market Size by 2032 | USD 44.01 Billion |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Product Type, By Application, and By End-user |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Growth Factors:
Several factors contribute to the growth of the Plasma Protein Therapeutics Market. The increasing prevalence of rare diseases and chronic conditions has led to a growing patient population requiring plasma-derived therapies. Technological innovations in plasma fractionation and purification techniques have enhanced the efficiency and safety of these therapeutic products, fostering market expansion. Additionally, a surge in research and development activities, coupled with strategic collaborations among key market players, has accelerated the introduction of novel plasma protein therapies, further fueling market growth.
Opportunities:
The Plasma Protein Therapeutics Market is ripe with opportunities for innovation and expansion. As the demand for plasma-derived therapies continues to rise globally, there is a significant opportunity for companies to explore untapped markets and broaden their product portfolios. Furthermore, advancements in biotechnology and personalized medicine open avenues for the development of customized plasma protein therapies, catering to specific patient needs. Emerging markets, particularly in Asia-Pacific and Latin America, present lucrative opportunities for market players to establish a strong foothold and address the unmet medical needs of diverse patient populations.
Challenges:
Despite the promising outlook, the Plasma Protein Therapeutics Market faces certain challenges. Regulatory complexities and stringent quality standards associated with plasma-derived products pose hurdles for market entry and product approvals. Additionally, concerns related to the potential transmission of infectious agents through plasma-derived therapies necessitate rigorous safety measures, adding to the overall operational challenges faced by industry players. Moreover, pricing pressures and reimbursement issues in some regions could impact the market’s growth trajectory, requiring companies to navigate complex economic landscapes.
Product Type
Within the product type segment, the market encompasses a variety of plasma-derived and recombinant proteins. Immunoglobulins, clotting factor concentrates, albumin, protease inhibitors, and alpha-1 antitrypsin are key constituents. Immunoglobulins play a crucial role in addressing immunodeficiency disorders and autoimmune diseases. Clotting factor concentrates are pivotal for managing bleeding disorders like hemophilia. Albumin finds application in fluid volume restoration and as a drug carrier, while protease inhibitors and alpha-1 antitrypsin serve specific therapeutic purposes.
Application
The application segment delineates the diverse therapeutic uses of plasma protein therapeutics. Immunoglobulins are applied in the treatment of immunodeficiency disorders and infections. Clotting factor concentrates find utility in managing bleeding disorders, particularly hemophilia. Albumin is versatile, finding application in fluid volume restoration and as a carrier for drugs. Protease inhibitors are crucial in treating conditions like HIV/AIDS, and alpha-1 antitrypsin is employed to manage genetic disorders affecting the lungs and liver.
End-user
The end-user categorization reflects the entities that utilize plasma protein therapeutics. Hospitals and clinics are major end-users, administering these therapies to patients across various medical conditions. Homecare settings are increasingly adopting plasma protein therapies, providing a convenient option for patients requiring regular treatment. Moreover, research institutions contribute to the end-user spectrum, engaging in ongoing studies and clinical trials to advance the understanding and application of plasma protein therapeutics.
Read Also: Radar Sensors Market Size is Expected to Worth of US$ 39.37 Bn in 2032
Recent Developments
- In December 2022, Biotest AG revealed the initiation of a clinical phase II pilot study for treating chronic hepatitis B with hyperimmunoglobulins at the Hanover Medical School, enrolling the first of 20 patients.
- In June 2022, Biotest AG reported a successful interim analysis of the phase III AdFIrst trial, assessing Fibrinogen in patients with acquired fibrinogen deficiency.
- In May 2020, Biotest AG completed the clinical trial 984, treating patients with congenital fibrinogen deficiency using the fibrinogen concentrate (BT524) for acute bleeding or prophylactic treatment before surgery.
- In July 2022, Takeda announced the positive outcome of the ADVANCE-1 Phase 3 clinical trial for HYQVIA in the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- In November 2022, Biotest AG received approval from the Paul-Ehrlich-Institute for the new intravenous immunoglobulin Yimmugo (IgG Next Generation) in Germany.
- In January 2022, Bio Products Laboratory (BPL) obtained a license from the NMPA to market ALBUMINEX 25% product in China.
- In March 2022, Grifols announced the approval of XEMBIFY, its 20% subcutaneous immunoglobulin, by several European Union member state health authorities and the U.K., to treat primary and select secondary immunodeficiency.
- In April 2022, Grifols completed the acquisition of Tiancheng (Germany) Pharmaceutical Holdings AG, which holds a significant stake in Biotest AG.
- In September 2022, Grifols signed a long-term agreement with Canadian Blood Services to enhance Canada’s self-sufficiency in immunoglobulin medicines.
Plasma Protein Therapeutics Market Players
- CSL Limited
- Grifols S.A.
- Takeda Pharmaceutical Company Limited
- Octapharma AG
- Biotest AG
- Kedrion S.p.A.
- Shire (acquired by Takeda)
- Bio Products Laboratory (BPL)
- Kamada Ltd.
- China Biologic Products Holdings, Inc.
- Octapharma Plasma, Inc.
- Sanquin
- LFB S.A.
- ADMA Biologics, Inc.
- Bioverativ (acquired by Sanofi)
Segments Covered in the Report
By Product Type
- Immunoglobulin
- Albumin
- Plasma derived factor VIII
- Others
By Application
- Hemophilia
- Idiopathic thrombocytopenic purpura
- Primary immunodeficiency disorder
- Others
By End-user
- Hospitals
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
Blog: https://www.dailytechbulletin.com/
Blog: https://www.autoindustrybulletin.com/
